The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States
Author
Abstract
Suggested Citation
DOI: 10.1007/s40273-020-00992-6
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.
Citations
Blog mentions
As found by EconAcademics.org, the blog aggregator for Economics research:- Journal round-up: PharmacoEconomics 39(4)
by Chris Sampson in The Academic Health Economists' Blog on 2021-06-15 06:00:05
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Niek Stadhouders & Xander Koolman & Christel van Dijk & Patrick Jeurissen & Eddy Adang, 2019. "The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function," Health Economics, John Wiley & Sons, Ltd., vol. 28(11), pages 1331-1344, November.
- Paul Revill & Simon Walker & Valentina Cambiano & Andrew Phillips & Mark J Sculpher, 2018. "Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-13, January.
- Aidan Hollis, 2016. "Sustainable Financing of Innovative Therapies: A Review of Approaches," PharmacoEconomics, Springer, vol. 34(10), pages 971-980, October.
- James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker & Jessica Ochalek & Mark Sculpher & Matthias Arnold, 2019. "Economic analysis for health benefits package design," Working Papers 165cherp, Centre for Health Economics, University of York.
- Anuj Tiwari & David J Blok & Mohammad Arif & Jan Hendrik Richardus, 2020. "Leprosy post-exposure prophylaxis in the Indian health system: A cost-effectiveness analysis," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 14(8), pages 1-12, August.
- Morton, Alec & Arulselvan, Ashwin & Thomas, Ranjeeta, 2018. "Allocation rules for global donors," Journal of Health Economics, Elsevier, vol. 58(C), pages 67-75.
- Charles Ebuka Okafor, 2021. "Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications," PharmacoEconomics - Open, Springer, vol. 5(3), pages 545-557, September.
- James O’Mahony & Diarmuid Coughlan, 2016. "The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?," PharmacoEconomics, Springer, vol. 34(1), pages 5-11, January.
- Claxton, Karl & Asaria, Miqdad & Chansa, Collins & Jamison, Julian & Lomas, James & Ochalek, Jessica & Paulden, Mike, 2019. "Accounting for timing when assessing health-related policies," LSE Research Online Documents on Economics 100038, London School of Economics and Political Science, LSE Library.
- Beth Woods & Claire Rothery & Paul Revill & Timothy Hallett & Andrew Phillips & Karl Claxton., 2018. "Setting research priorities in Global Health:Appraising the value of evidence generation activities to support decision-making in health care," Working Papers 155cherp, Centre for Health Economics, University of York.
- Culyer, Anthony J., 2016.
"Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use,"
Health Economics, Policy and Law, Cambridge University Press, vol. 11(4), pages 415-432, October.
- Anthony J Culyer, 2015. "Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use," Working Papers 121cherp, Centre for Health Economics, University of York.
- Laia Cirera & Beatriz Galatas & Sergi Alonso & Krijn Paaijmans & Miler Mamuquele & Helena Martí-Soler & Caterina Guinovart & Humberto Munguambe & Fabião Luis & Hoticha Nhantumbo & Júlia Montañà & Quiq, 2020. "Moving towards malaria elimination in southern Mozambique: Cost and cost-effectiveness of mass drug administration combined with intensified malaria control," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-17, July.
- Amani Mori & Ole Norheim & Bjarne Robberstad, 2016. "Budget Impact Analysis of Using Dihydroartemisinin–Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania," PharmacoEconomics, Springer, vol. 34(3), pages 303-314, March.
- Byrne, Dominic & Kwak, Do Won & Tang, Kam Ki & Yazbeck, Myra, 2023.
"Spillover effects of retirement: Does health vulnerability matter?,"
Economics & Human Biology, Elsevier, vol. 48(C).
- Dominic Byrne & Do Won Kwak & Kam Ki Tang & Myra Yazbeck, 2020. "Spillover Effects of Retirement: does health vulnerability matter?," Discussion Papers Series 620, School of Economics, University of Queensland, Australia.
- Dominic Byrne & Do Won Kwak & Kam Ki Tang & Myra Yazbeck, 2021. "Spillover Effects of Retirement: does health vulnerability matter?," Discussion Papers Series 643, School of Economics, University of Queensland, Australia.
- Halimatou Diawara & Patrick Walker & Matt Cairns & Laura C Steinhardt & Fatou Diawara & Beh Kamate & Laetitia Duval & Elisa Sicuri & Issaka Sagara & Aboubacar Sadou & Jules Mihigo & Erin Eckert & Alas, 2021.
"Cost-effectiveness of district-wide seasonal malaria chemoprevention when implemented through routine malaria control programme in Kita, Mali using fixed point distribution,"
Post-Print
hal-03184961, HAL.
- Halimatou Diawara & Patrick Walker & Matt Cairns & Laura C Steinhardt & Fatou Diawara & Beh Kamate & Laetitia Duval & Elisa Sicuri & Issaka Sagara & Aboubacar Sadou & Jules Mihigo & Erin Eckert & Alas, 2021. "Cost-effectiveness of district-wide seasonal malaria chemoprevention when implemented through routine malaria control programme in Kita, Mali using fixed point distribution," Université Paris1 Panthéon-Sorbonne (Post-Print and Working Papers) hal-03184961, HAL.
- Caitlin M Dugdale & Tamsin K Phillips & Landon Myer & Emily P Hyle & Kirsty Brittain & Kenneth A Freedberg & Lucy Cunnama & Rochelle P Walensky & Allison Zerbe & Milton C Weinstein & Elaine J Abrams &, 2019. "Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa," PLOS ONE, Public Library of Science, vol. 14(11), pages 1-18, November.
- Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger, 2016. "Supporting the development of an essential health package: principles and initial assessment for Malawi," Working Papers 136cherp, Centre for Health Economics, University of York.
- Markiewicz Olimpia, 2021. "Value of Life Year and Cost-Effectiveness Thresholds: The Case of Poland," Central European Economic Journal, Sciendo, vol. 8(55), pages 256-268, January.
- Samuel N. Frempong & Andrew J. Sutton & Clare Davenport & Pelham Barton, 2020. "Early Economic Evaluation to Identify the Necessary Test Characteristics of a New Typhoid Test to be Cost Effective in Ghana," PharmacoEconomics - Open, Springer, vol. 4(1), pages 143-157, March.
- Marwân-al-Qays Bousmah & Marie Libérée Nishimwe & Tamara Tovar-Sanchez & Martial Lantche Wandji & Mireille Mpoudi-Etame & Gwenaëlle Maradan & Pierrette Omgba Bassega & Marie Varloteaux & Alice Montoyo, 2021.
"Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial),"
PharmacoEconomics, Springer, vol. 39(3), pages 331-343, March.
- Marwân-Al-Qays Bousmah & Marie Libérée Nishimwe & Tamara Tovar-Sanchez & Martial Lantche Wandji & Mireille Mpoudi-Etame & Gwenaëlle Maradan & Pierrette Omgba Bassega & Marie Varloteaux & Alice Montoyo, 2021. "Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)," Post-Print hal-03174666, HAL.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:39:y:2021:i:4:d:10.1007_s40273-020-00992-6. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.